Tag: ACW
Actinogen Medical announces ‘breakthrough’ study results for Alzheimer’s drug Xanamem
Actinogen Medical (ASX: ACW) has announced “breakthrough” results from its XanaHES higher dose safety study first initiated last year.
The results reaffirm the foundational hypothesis that reducing...
Actinogen Medical phase two Alzheimer’s clinical trial disappoints
Biotech company Actinogen Medical (ASX: ACW) has reported a mixed bag of results including some disappointing outcomes from its XanADu phase two clinical trial treating patients with mild dementia due...
Actinogen Medical attracts US biotech investor as Alzheimer’s XanADu study remains on track
Actinogen Medical (ASX: ACW) has received a double-shot of positive news earlier today after the biotech company received the all-clear from the Data Safety and Monitoring Board (DSMB) to continue its...
Actinogen moves towards XanADu starting line to treat Alzheimer’s disease
Biotech company Actinogen Medical (ASX: ACW) has confirmed that it has obtained half of the required patients in order to conduct its landmark Phase 2 clinical trial of Xanamem, a drug candidate to tr...